Renal Tubular Acidosis Types
Renal tubular acidosis (RTA) comprises four distinct types (1,2,3, and 4) characterized by normal anion gap metabolic acidosis with hyperchloremia, each with unique pathophysiology involving specific tubular transport defects.
Type 1 RTA (Distal RTA)
Type 1 RTA results from impaired hydrogen ion secretion by type A intercalated cells in the collecting duct, leading to inability to acidify urine below pH 5.5 1, 2, 3.
Pathophysiology
- Defective acid excretion in the distal tubule/collecting duct
- Genetic mutations affecting H+-ATPase or Cl-/HCO3- exchanger
- Results in inability to maintain adequate urinary acidification
Clinical Presentation
- Growth retardation and failure to thrive in children
- Nephrocalcinosis and nephrolithiasis (from hypercalciuria and hypocitraturia)
- Bone disease (rickets in children, osteomalacia/osteoporosis in adults)
- Hypokalemia (often severe, causing muscle weakness or paralysis)
- Polyuria and dehydration 4, 5
Management
Lifelong alkali therapy targeting plasma bicarbonate 23-28 mEq/L is essential to prevent all complications 5. Sodium bicarbonate or potassium citrate (1-3 mEq/kg/day) should be administered, with potassium citrate preferred when hypokalemia coexists 3, 4.
Type 2 RTA (Proximal RTA)
Type 2 RTA stems from defective bicarbonate reabsorption in the proximal tubule, with preserved distal acidification capacity 1, 2.
Pathophysiology
- Impaired HCO3- reclamation in proximal tubule (normally reabsorbs 80-90% of filtered bicarbonate)
- Often part of Fanconi syndrome with multiple proximal tubular defects
- Can acidify urine to pH <5.5 once serum bicarbonate falls below reabsorptive threshold
Clinical Presentation
- Growth retardation and rickets (especially when part of Fanconi syndrome)
- Hypokalemia (typically less severe than type 1)
- Associated findings: hypophosphatemia, glycosuria, aminoaciduria, hypouricemia
- Polyuria 4
Management
Higher doses of alkali therapy (10-15 mEq/kg/day) are required compared to distal RTA due to urinary bicarbonate wasting 3, 4. When Fanconi syndrome is present, add phosphate supplementation (1-3 g/day) and vitamin D (calcitriol 0.25-2 mcg/day) to address rickets 4.
Type 3 RTA (Mixed RTA)
Type 3 RTA is an extremely rare variant combining features of both type 1 and type 2 RTA 1, 2.
Key Features
- Historically described but rarely diagnosed in modern practice
- Exhibits both proximal bicarbonate wasting and distal acidification defects
- Management follows principles of both type 1 and type 2 RTA
Type 4 RTA (Hyperkalemic RTA)
Type 4 RTA results from aldosterone deficiency or resistance, causing hyperkalemia with metabolic acidosis 2, 3.
Pathophysiology
- Aldosterone deficiency (hyporeninemic hypoaldosteronism) or resistance
- Impaired potassium and hydrogen ion secretion in collecting duct
- Most common form of RTA in adults
Clinical Presentation
- Hyperkalemia (distinguishing feature from other RTA types)
- Mild metabolic acidosis (bicarbonate typically 17-22 mEq/L)
- Often associated with diabetes mellitus or chronic kidney disease
- Less severe bone disease compared to types 1 and 2 3
Management
Primary goal is lowering serum potassium through dietary potassium restriction (<2-3 g/day) and addressing underlying cause 3. Consider:
- Loop or thiazide diuretics to enhance potassium excretion
- Fludrocortisone (0.1-0.3 mg/day) if aldosterone deficiency confirmed
- Newer potassium binders (patiromer, sodium zirconium cyclosilicate) for refractory hyperkalemia
- Alkali therapy only if acidosis persists after potassium correction 3
Diagnostic Approach
Initial Assessment
- Confirm normal anion gap metabolic acidosis (anion gap <12 mEq/L)
- Check serum potassium: Hypokalemia suggests type 1 or 2; hyperkalemia indicates type 4
- Measure urine pH during acidemia:
- pH >5.5 with acidemia → type 1 RTA
- pH <5.5 → type 2 or 4 RTA
- Calculate urine anion gap (Na+ + K+ - Cl-):
- Positive → impaired NH4+ excretion (RTA)
- Negative → appropriate renal response (GI losses)
Distinguishing Type 1 from Type 2
- Fractional excretion of bicarbonate: >15% suggests type 2 RTA
- Urine pH after bicarbonate loading: Remains >5.5 in type 1; becomes alkaline (>7.5) in type 2
- Associated Fanconi syndrome features point to type 2 6, 3
Critical Pitfalls
Never delay alkali therapy in children with type 1 or 2 RTA while awaiting genetic testing—irreversible growth retardation and bone disease develop rapidly 5. The target bicarbonate of 23-28 mEq/L is non-negotiable for preventing complications 5.
In type 4 RTA, avoid potassium-sparing diuretics, ACE inhibitors, and ARBs which will exacerbate hyperkalemia 3. Address hyperkalemia before considering alkali therapy, as bicarbonate administration can worsen potassium levels.
Incomplete distal RTA may present with nephrocalcinosis/nephrolithiasis without overt acidosis—maintain high suspicion in young patients with kidney stones 7.